Series B round led by Morningside Ventures provides foundation to accelerate the drug development of first-in-class immune-resetting therapies. (London UK and Boston USA, 21 September 2020) Immune Regulation Limited (“Immune Regulation”), a US and UK based clinical stage biotechnology company, today announced the closing of a Series B funding round led by Boston based Morningside